Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1

Interventions

Paclitaxel 4Specimen Handling 3Magnetic Resonance Spectroscopy 3Trastuzumab 2Taxes 2Tamoxifen 2Interleukin-2 2Fluorouracil 2Cyclophosphamide 2Anastrozole 2trastuzumab biosimilar HLX02 1tivozanib 1taletrectinib 1palbociclib 1fluzoparib 1exemestane 1eribulin 1binimetinib 1atezolizumab 1aldesleukin 1Tomography, Optical Coherence 1Testosterone Propionate 1Testosterone 1Tablets 1Receptors, Chimeric Antigen 1Radiotherapy 1PF-05280014 1Ontruzant 1Ogivri 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × taletrectinib × Breast × Clear all
NCT06214793 2025-05-01

Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)

Case Comprehensive Cancer Center

Phase 2 Suspended
61 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡